Clinical Trial Update: A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use [Phase 1, Phase 2]

View source ↗

Summary

An imaging study using [68]Ga-HA-DOTATATE to identify/diagnose tumors with somatostatin receptors is being evaluated for safety and diagnostic performance in Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• [68]Ga-HA-DOTATATE (gallium-68 HA-DOTATATE)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: RECRUITING